Sign in

    Bryan Cheng

    Senior Biotech Analyst at J.P. Morgan

    Bryan Cheng is a Senior Biotech Analyst at J.P. Morgan, specializing in biotechnology equity research with a focus on leading and innovative biotech companies. He provides in-depth coverage of major biotechnology firms and delivers actionable investment insights, contributing to the firm's reputation for top-tier healthcare research. Cheng has established his career in New York and is recognized for his analytic rigor and deep sector knowledge, holding the Senior Biotech Analyst position at J.P. Morgan following previous industry experience. His professional credentials include expertise in equity analysis and a robust track record within the biotechnology investment community.

    Bryan Cheng's questions to Coherus Oncology (CHRS) leadership

    Bryan Cheng's questions to Coherus Oncology (CHRS) leadership • Q4 2024

    Question

    Asked about LOQTORZI's real-world user stickiness, physician willingness to switch from off-label Keytruda, and what constitutes good data from the upcoming CCR8 intratumoral biopsies.

    Answer

    The company noted high physician satisfaction and repeat use of LOQTORZI, though opportunities are infrequent due to the rarity of NPC. They are actively working to convert off-label users with data and guideline education. Good biopsy data would show Treg depletion and an increase in CD8 T cells within the tumor.

    Ask Fintool Equity Research AI